{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"4.1","value":"3.9"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"6.2","value":"2.0"},{"groupId":"OG004","lowerLimit":"3.9","upperLimit":"7.9","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"tmax was defined as the time of the maximum observed concentration of INCB001158.","dispersionType":"Full Range","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"},{"description":"INCB001158 was administered orally at 50 mg BID in combination with pembrolizumab at 200 mg IV Q3W to participants with moderately impaired renal function.","id":"OG004","title":"Part 1C: INCB001158 50 mg + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"PK Population. Analysis was conducted to compare INCB001158 50 mg + pembrolizumab in participants with renal impairment with INCB001158 50 mg or 75 mg in participants with normal renal function. It was pre-specified to collect data for only the Part 1A INCB001158 50 mg, Part 1A: INCB001158 75 mg, and Part 1C: INCB001158 50 mg + Pembrolizumab arms. Participants in the INCB001158 100 mg and 150 mg arms did not contribute to the analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: predose; 0.5, 1, 2, 4, 6, 8, 12, and 24 (Part 1A only) hours post-dose.","title":"Tmax of INCB001158 in Participants With Renal Impairment (Part 1C) and Normal Renal Function (Part 1A)","type":"SECONDARY","unitOfMeasure":"hours"}